Aevi Genomic Medicine (NASDAQ: GNMX) and Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.
Insider and Institutional Ownership
20.8% of Aevi Genomic Medicine shares are held by institutional investors. Comparatively, 87.8% of Jazz Pharmaceuticals PLC shares are held by institutional investors. 15.2% of Aevi Genomic Medicine shares are held by insiders. Comparatively, 4.3% of Jazz Pharmaceuticals PLC shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Aevi Genomic Medicine and Jazz Pharmaceuticals PLC’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Aevi Genomic Medicine||N/A||N/A||-$37.80 million||($1.02)||-1.25|
|Jazz Pharmaceuticals PLC||$1.54 billion||5.48||$758.97 million||$6.45||21.78|
Jazz Pharmaceuticals PLC has higher revenue and earnings than Aevi Genomic Medicine. Aevi Genomic Medicine is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals PLC, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of recent ratings and target prices for Aevi Genomic Medicine and Jazz Pharmaceuticals PLC, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Aevi Genomic Medicine||0||1||1||0||2.50|
|Jazz Pharmaceuticals PLC||0||5||15||0||2.75|
Aevi Genomic Medicine presently has a consensus price target of $4.25, indicating a potential upside of 232.03%. Jazz Pharmaceuticals PLC has a consensus price target of $181.20, indicating a potential upside of 29.00%. Given Aevi Genomic Medicine’s higher probable upside, equities analysts plainly believe Aevi Genomic Medicine is more favorable than Jazz Pharmaceuticals PLC.
This table compares Aevi Genomic Medicine and Jazz Pharmaceuticals PLC’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Aevi Genomic Medicine||N/A||-125.94%||-106.93%|
|Jazz Pharmaceuticals PLC||25.69%||22.75%||9.14%|
Volatility and Risk
Aevi Genomic Medicine has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals PLC has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500.
Jazz Pharmaceuticals PLC beats Aevi Genomic Medicine on 10 of the 12 factors compared between the two stocks.
Aevi Genomic Medicine Company Profile
Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohns disease. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.
Jazz Pharmaceuticals PLC Company Profile
Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder. Its marketed products and late-stage product candidate are Xyrem (sodium oxybate) oral solution, Luvox CR (fluvoxamine maleate) Extended-Release Capsules and JZP-6 (sodium oxybate). Its other product candidates in clinical development are oral tablet forms of sodium oxybate; JZP-8 (intranasal clonazepam); JZP-4 (elpetrigine), and JZP-7 (ropinirole gel).
Receive News & Ratings for Aevi Genomic Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.